George A Diamond

Summary

Country: USA

Publications

  1. ncbi Rosiglitazone and cardiovascular risk
    Sanjay Kaul
    Division of Cardiology, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Curr Atheroscler Rep 10:398-404. 2008
  2. ncbi COURAGE under fire: on the management of stable coronary disease
    George A Diamond
    Division of Cardiology, Cedars Sinai Medical Center, and the David Geffen School of Medicine, University of California, Los Angeles, California, USA
    J Am Coll Cardiol 50:1604-9. 2007
  3. ncbi Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death
    George A Diamond
    Cedars Sinai Medical Center and David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA
    Ann Intern Med 147:578-81. 2007
  4. ncbi Screen testing cardiovascular prevention in asymptomatic diabetic patients
    George A Diamond
    Division of Cardiology, Cedars Sinai Medical Center, Los Angeles, California, USA
    J Am Coll Cardiol 49:1915-7. 2007
  5. ncbi The things to come of SHAPE: cost and effectiveness of cardiovascular prevention
    George A Diamond
    Division of Cardiology, Cedars Sinai Medical Center, and David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA
    Am J Cardiol 99:1013-5. 2007
  6. ncbi An orwellian discourse on the meaning and measurement of noninferiority
    George A Diamond
    Division of Cardiology, Cedars Sinai Medical Center, Los Angeles, California, USA
    Am J Cardiol 99:284-7. 2007
  7. ncbi From here to eternity: a unified kinetic model for the pathophysiology of atherosclerotic events
    George A Diamond
    Division of Cardiology, Cedars Sinai Medical Center, Los Angeles, Calif, USA
    Am J Med 120:5-11. 2007
  8. ncbi Bayesian classification of clinical practice guidelines
    George A Diamond
    Division of Cardiology, Cedars Sinai Medical Center, and the David Geffen School of Medicine, University of California, Los Angeles, CA, USA
    Arch Intern Med 169:1431-5. 2009
  9. ncbi Hazardous to your health: kinetic foundations of risk stratification and therapeutic triage
    George A Diamond
    Division of Cardiology, Cedars Sinai Medical Center, and David Geffen School of Medicine, University of California, Los Angeles, USA
    Am J Med 119:275.e1-6. 2006
  10. ncbi Prior convictions: Bayesian approaches to the analysis and interpretation of clinical megatrials
    George A Diamond
    Division of Cardiology, Cedars Sinai Medical Center, and the School of Medicine, University of California, Los Angeles, California, USA
    J Am Coll Cardiol 43:1929-39. 2004

Detail Information

Publications31

  1. ncbi Rosiglitazone and cardiovascular risk
    Sanjay Kaul
    Division of Cardiology, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Curr Atheroscler Rep 10:398-404. 2008
    ..We conclude that the data showing the increased risk for myocardial infarction and death from cardiovascular disease for diabetic patients taking rosiglitazone are inconclusive...
  2. ncbi COURAGE under fire: on the management of stable coronary disease
    George A Diamond
    Division of Cardiology, Cedars Sinai Medical Center, and the David Geffen School of Medicine, University of California, Los Angeles, California, USA
    J Am Coll Cardiol 50:1604-9. 2007
    ..We herein reevaluate the evidence with regard to each of these points, and conclude that COURAGE indeed provides relevant new information to assist the practitioner in the appropriate management of patients with stable coronary disease...
  3. ncbi Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death
    George A Diamond
    Cedars Sinai Medical Center and David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA
    Ann Intern Med 147:578-81. 2007
    ..We conclude that the risk for myocardial infarction and death from cardiovascular disease for diabetic patients taking rosiglitazone is uncertain: Neither increased nor decreased risk is established...
  4. ncbi Screen testing cardiovascular prevention in asymptomatic diabetic patients
    George A Diamond
    Division of Cardiology, Cedars Sinai Medical Center, Los Angeles, California, USA
    J Am Coll Cardiol 49:1915-7. 2007
    ..This analysis shows that unconditional treatment is the dominant strategy, costing 24% less ($3.2 billion) and preventing 25% more (16,800) atherosclerotic events annually on a national basis...
  5. ncbi The things to come of SHAPE: cost and effectiveness of cardiovascular prevention
    George A Diamond
    Division of Cardiology, Cedars Sinai Medical Center, and David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA
    Am J Cardiol 99:1013-5. 2007
    ..In conclusion, greater attention should be paid to improving the population-wide delivery of and long-term adherence to proven preventive therapy than to the identification of "high-risk" treatment targets...
  6. ncbi An orwellian discourse on the meaning and measurement of noninferiority
    George A Diamond
    Division of Cardiology, Cedars Sinai Medical Center, Los Angeles, California, USA
    Am J Cardiol 99:284-7. 2007
    ..In conclusion, the resultant probabilistic measures thereby render the meaning of noninferiority more transparent and clinically relevant...
  7. ncbi From here to eternity: a unified kinetic model for the pathophysiology of atherosclerotic events
    George A Diamond
    Division of Cardiology, Cedars Sinai Medical Center, Los Angeles, Calif, USA
    Am J Med 120:5-11. 2007
    ....
  8. ncbi Bayesian classification of clinical practice guidelines
    George A Diamond
    Division of Cardiology, Cedars Sinai Medical Center, and the David Geffen School of Medicine, University of California, Los Angeles, CA, USA
    Arch Intern Med 169:1431-5. 2009
    ..We conclude that this quantitative schema has the potential to improve the quality and cost of evidence-based clinical management...
  9. ncbi Hazardous to your health: kinetic foundations of risk stratification and therapeutic triage
    George A Diamond
    Division of Cardiology, Cedars Sinai Medical Center, and David Geffen School of Medicine, University of California, Los Angeles, USA
    Am J Med 119:275.e1-6. 2006
    ..Clinical risk stratification nevertheless relies only on the former...
  10. ncbi Prior convictions: Bayesian approaches to the analysis and interpretation of clinical megatrials
    George A Diamond
    Division of Cardiology, Cedars Sinai Medical Center, and the School of Medicine, University of California, Los Angeles, California, USA
    J Am Coll Cardiol 43:1929-39. 2004
    ..Accordingly, the Bayesian approach should be employed more widely in the design, analysis, and interpretation of clinical megatrials...
  11. ncbi Making sense of noninferiority: a clinical and statistical perspective on its application to cardiovascular clinical trials
    Sanjay Kaul
    Division of Cardiology, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California, Los Angeles, CA 90048, USA
    Prog Cardiovasc Dis 49:284-99. 2007
    ....
  12. ncbi As time goes by: current status and future directions in the controversy over stenting
    Sanjay Kaul
    Division of Cardiology, Cedars Sinai Medical Center, and the David Geffen School of Medicine, University of California, Los Angeles, California 90048, USA
    J Am Coll Cardiol 50:128-37. 2007
    ....
  13. ncbi The JUPITER trial: myth or reality?
    Ryan P Morrissey
    Cedars Sinai Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Curr Atheroscler Rep 13:413-21. 2011
    ..Given these limitations, the attendant societal health policy implications remain largely unknown...
  14. ncbi Current status and future trends in drug-eluting stents
    Sanjay Kaul
    Division of Cardiology, Cedars-Sinai Medical Center and the David Geffen School of Medicine, University of California, Los Angeles, CA 90048, USA
    Am Heart Hosp J 5:165-8. 2007
  15. ncbi Statins in acute coronary syndromes: do the guideline recommendations match the evidence?
    Ryan P Morrissey
    Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    J Am Coll Cardiol 54:1425-33. 2009
    ..On the basis of these observations, and despite a compelling pathophysiologic rationale, the justification for current Class I, Level of Evidence: A recommendation for statin therapy in patients with ACS remains open to question...
  16. ncbi Trials and tribulations of non-inferiority: the ximelagatran experience
    Sanjay Kaul
    Division of Cardiology, Cedars Sinai Medical Center, and the David Geffen School of Medicine, University of California, Los Angeles, California 90048, USA
    J Am Coll Cardiol 46:1986-95. 2005
    ..Such determinations of non-inferiority are highly dependent on the underlying assumptions, and graphical sensitivity analyses make this dependence explicit...
  17. ncbi Role of clopidogrel in managing atherothrombotic cardiovascular disease
    Shervin Eshaghian
    Cedars Sinai Medical Center and the David Geffen School of Medicine, University of California, Los Angeles, California 90048, USA
    Ann Intern Med 146:434-41. 2007
    ....
  18. ncbi Narrative review: drug-eluting stents for the management of restenosis: a critical appraisal of the evidence
    Roderick Tung
    Cedars-Sinai Medical Center, David Geffen School of Medicine, and University of California, Los Angeles, Los Angeles, California 90048, USA
    Ann Intern Med 144:913-9. 2006
    ....
  19. ncbi Good enough: a primer on the analysis and interpretation of noninferiority trials
    Sanjay Kaul
    Division of Cardiology, Cedars Sinai Medical Center and David Geffen School of Medicine, University of California, Los Angeles, California 90048, USA
    Ann Intern Med 145:62-9. 2006
    ....
  20. ncbi Continuous probabilistic prediction of angiographically significant coronary artery disease using electron beam tomography
    Matthew J Budoff
    Division of Cardiology, Harbor UCLA Research and Education Institute, Torrance, Calif 90502 2064, USA
    Circulation 105:1791-6. 2002
    ..Such a model could greatly facilitate clinical triage in symptomatic patients with no known CAD...
  21. ncbi On reporting of effect size in randomized clinical trials
    George A Diamond
    Division of Cardiology, Cedars Sinai Medical Center and University of California, Los Angeles, California, USA
    Am J Cardiol 111:613-7. 2013
    ..In conclusion, our results have shown that composite measures of effect size communicate the clinical importance of trial results better than do conventional assessments of risk reduction and statistical significance...
  22. ncbi By desperate appliance relieved? On the clinical relevance of risk stratification to therapeutic decision-making
    George A Diamond
    Division of Cardiology, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California, Los Angeles, California
    Am J Cardiol 109:919-23. 2012
    ..Instead, risk stratification guidelines specific to a particular disease and a particular treatment should be founded on prospective empiric validation...
  23. ncbi Trial and error. How to avoid commonly encountered limitations of published clinical trials
    Sanjay Kaul
    Division of Cardiology, Cedars Sinai Medical Center, and the David Geffen School of Medicine, University of California, Los Angeles, California 90048 1804, USA
    J Am Coll Cardiol 55:415-27. 2010
    ..Accordingly, this review highlights these limitations using numerous examples of published clinical trials and describes ways to overcome these limitations, thereby improving the interpretability of research findings...
  24. ncbi Dronedarone for atrial fibrillation have we expanded the antiarrhythmic armamentarium?
    David Singh
    Division of Cardiology, Cedars Sinai Medical Center, and the David Geffen School of Medicine, University of California, Los Angeles, California 90048, USA
    J Am Coll Cardiol 55:1569-76. 2010
    ..We conclude that the available data support the use of dronedarone in select patient populations as a second- or third-line agent...
  25. ncbi Prospective validation of a quantitative method for differentiating ischemic versus nonischemic cardiomyopathy by technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography
    Siu Sun Yao
    Division of Cardiology, St Luke s Roosevelt Hospital Center and Columbia University College of Physicians and Surgeons, New York, New York 10019, USA
    Clin Cardiol 27:615-20. 2004
    ..Quantitative analysis of perfusion patterns among patients with LV dysfunction offers an opportunity for developing criteria to differentiate ischemic from nonischemic cardiomyopathy...
  26. ncbi Rosiglitazone and cardiovascular risk
    George A Diamond
    N Engl J Med 357:938-9; author reply 939-40. 2007
  27. ncbi Prevention and treatment: a tale of two strategies
    George A Diamond
    J Am Coll Cardiol 51:46-8. 2008
  28. ncbi The disconnect between practice guidelines and clinical practice--stressed out
    George A Diamond
    JAMA 300:1817-9. 2008
  29. ncbi Women's Ischemic Syndrome Evaluation: current status and future research directions: report of the National Heart, Lung and Blood Institute workshop: October 2-4, 2002: Section 1: diagnosis of stable ischemia and ischemic heart disease
    Carl J Pepine
    Circulation 109:e44-6. 2004
  30. ncbi Predicting cardiovascular events with coronary calcium scoring
    William S Weintraub
    N Engl J Med 358:1394-6. 2008
  31. ncbi DTCA for PTCA--crossing the line in consumer health education?
    William E Boden
    Division of Cardiovascular Medicine, University at Buffalo Schools of Medicine and Public Health, and Buffalo General Hospital, Buffalo, NY, USA
    N Engl J Med 358:2197-200. 2008